Sagimet Biosciences (SGMT) Income Statement (2022 - 2025)
Income Statement report data from Mar 31, 2022 to Dec 31, 2025 for Sagimet Biosciences (SGMT).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jul 31, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | ||||||||||||||||
Total Revenue | - | - | - | - | - | - | - | - | 2.00M (0.00%) | 2.00M | - | - | - | - | - | - |
Operating Expenses | ||||||||||||||||
Research And Development | 6.73M (-30.83%) | 9.73M (+34.21%) | 7.25M (-52.74%) | 15M (+7.88%) | 14M (+12.41%) | 13M (+100.48%) | 6.31M (+19.96%) | 5.26M (+6.05%) | 4.96M | - | 4.68M (+4.23%) | 4.49M (-61.66%) | 12M (+71.20%) | 6.84M (+7.38%) | 6.37M | - |
Selling General And Administrative | 4.03M (-12.39%) | 4.60M (-1.71%) | 4.68M (+3.54%) | 4.52M (+13.57%) | 3.98M (-6.35%) | 4.25M (-0.70%) | 4.28M (+21.94%) | 3.51M (-21.83%) | 4.49M | - | 2.38M (+4.39%) | 2.28M (-48.42%) | 4.42M (+420.00%) | 850K (-2.30%) | 870K | - |
Operating Expenses | 11M (-24.84%) | 14M (+20.12%) | 12M (-39.93%) | 20M (+9.12%) | 18M (+7.69%) | 17M (+59.58%) | 11M (+20.75%) | 8.77M (-7.20%) | 9.45M | - | 7.06M (+4.28%) | 6.77M (-58.03%) | 16M (+109.75%) | 7.69M (+6.22%) | 7.24M | - |
Operating Income | ||||||||||||||||
Operating Income | -10.76M (-24.91%) | -14.33M (+20.22%) | -11.92M (-39.98%) | -19.86M (+9.18%) | -18.19M (+7.63%) | -16.90M (+59.58%) | -10.59M (+20.75%) | -8.77M (+17.72%) | -7.45M | - | -7.06M (+4.44%) | -6.76M (-58.09%) | -16.13M (+109.75%) | -7.69M (+6.22%) | -7.24M | - |
Ebit | -10.76M (-24.91%) | -14.33M (+20.22%) | -11.92M (-39.98%) | -19.86M (+9.18%) | -18.19M (+7.63%) | -16.90M (+59.58%) | -10.59M (+20.75%) | -8.77M (+17.72%) | -7.45M | - | -7.06M (+4.44%) | -6.76M (-8.65%) | -7.40M (-3.77%) | -7.69M (+6.22%) | -7.24M (-17.07%) | -8.73M |
EBITDA | -9.57M (-25.87%) | -12.91M (+24.25%) | -10.39M (-42.85%) | -18.18M (+12.22%) | -16.20M (+10.81%) | -14.62M (+80.05%) | -8.12M (+22.47%) | -6.63M (+4.41%) | -6.35M | - | -6.78M (+2.88%) | -6.59M (-8.34%) | -7.19M (-3.75%) | -7.47M (+5.21%) | -7.10M (-18.67%) | -8.73M |
Other Income / Expenses | ||||||||||||||||
Other Non Operating Income | 5.85M (+309.09%) | 1.43M (-7.14%) | 1.54M (-8.88%) | 1.69M (-80.99%) | 8.89M (+289.91%) | 2.28M (-7.69%) | 2.47M (+15.42%) | 2.14M (+94.55%) | 1.10M | - | 270K (+50.00%) | 180K (-67.86%) | 560K (+154.55%) | 220K (+57.14%) | 140K | - |
Net Income | ||||||||||||||||
Net Income From Continuing Operations | -9.57M (-25.87%) | -12.91M (+24.25%) | -10.39M (-42.85%) | -18.18M (+12.22%) | -16.20M (+10.81%) | -14.62M (+80.05%) | -8.12M (+22.47%) | -6.63M (+4.41%) | -6.35M | - | -6.78M (+2.88%) | -6.59M (-8.34%) | -7.19M (-3.75%) | -7.47M (+5.21%) | -7.10M (-18.67%) | -8.73M |
Net Income | -9.57M (-25.87%) | -12.91M (+24.25%) | -10.39M (-42.85%) | -18.18M (+12.22%) | -16.20M (+10.81%) | -14.62M (+80.05%) | -8.12M (+22.47%) | -6.63M (+4.41%) | -6.35M | - | -6.78M (+2.88%) | -6.59M (-8.34%) | -7.19M (-3.75%) | -7.47M (+5.21%) | -7.10M (-18.67%) | -8.73M |
Comprehensive Income Net Of Tax | -51.15M (+297.44%) | -12.87M (+23.39%) | -10.43M (-42.94%) | -18.28M (-59.71%) | -45.37M (+220.64%) | -14.15M (+73.62%) | -8.15M (+22.56%) | -6.65M (+4.72%) | -6.35M | - | -6.77M (+3.83%) | -6.52M (-78.68%) | -30.58M (+306.65%) | -7.52M (+4.30%) | -7.21M | - |